Loading...
•
Jun 30, 2023
Gossamer Bio Q2 2023 Earnings Report
Announced second quarter 2023 financial results and provided business update
Key Takeaways
Gossamer Bio reported a net loss of $42.5 million for the second quarter ended June 30, 2023. The company's cash, cash equivalents, and marketable securities totaled $162.1 million as of June 30, 2023, which, combined with proceeds from a July private placement, is expected to fund operations into the first half of 2026.
Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23
Additional Data from TORREY Open-Label Extension Expected in 4Q23 or 1Q24
Cash, Cash Equivalents & Marketable Securities totaled $374 Million, as of June 30, 2023, Pro Forma for Gross Proceeds of $212 Million from a Private Placement Financing in July 2023
Net loss for the quarter ended June 30, 2023, was $42.5 million, or $0.45 per share
Forward Guidance
Gossamer Bio anticipates initiating the Phase 3 PROSERA Study in the third quarter of 2023 and expects current funds to support operations into the first half of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...